PubMed Health⌕ Search

Biomedical subjects

Piotr Skalba

Publications and source records attributed to Piotr Skalba.

2 recordsLinked to original sources

Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma.

The aim of this study was to investigate the expression of genes coding aromatase and 5-alpha-reductase type 1 and type 2 in endometrial adenocarcinoma, with parallel analysis of testosterone concentrations in serum isolated from blood of basilic and ovarian vein. A significant difference between the copy numbers of mRNA for 5-alpha-reductase type 1 and type 2 was disclosed. The content of the mRNA copies was higher for 5-alpha-reductase type 2 than for type 1. We noted a positive correlation between the mRNA copy number for aromatase and 5-alpha-reductase type 1 as well as between the mRNA copy number for aromatase and 5-alpha-reductase type 2. A positive correlation was disclosed between the mRNA copy number for 5-alpha-reductase type 1 and type 2. We concluded that in tissues of endometrial adenocarcinoma, there is expression of aromatase and 5-alpha-reductase type 1 and 2 genes, and that the expression of aromatase and 5-alpha-reductase genes in tissues of endometrial adenocarcinoma is not controlled by testosterone.

3-Oxo-5-alpha-Steroid 4-Dehydrogenase↗

[HRT in 2006].

According to present terminology, the name: hormonal replacement therapy (as the use of ovarian hormones in postmenopausal women) is replaced by the systemic estrogen therapy (ET) and combined combined estrogen-progestogen therapy (EPT). Treatment with estrogen and progestagens in this period of women's life is accepted intervention only when the strict defined conditions of this therapy are maintained. This paper introduces present rules of the use of systemic ET and EPT according to statements of experts who are interested of menopausal women' treatment.

Estrogen Replacement Therapy↗